GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of FOLD
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Red day on Wednesday for Amicus Therapeutics stock after losing 0.0947%
(Updated on Apr 17, 2024)

Sell candidate since Mar 12, 2024 Loss -10.52% PDF

The Amicus Therapeutics stock price fell by -0.0947% on the last day (Wednesday, 17th Apr 2024) from $10.56 to $10.55. It has now fallen 6 days in a row. During the last trading day the stock fluctuated 1.62% from a day low at $10.49 to a day high of $10.66. The price has fallen in 7 of the last 10 days and is down by -7.21% for this period. Volume has increased on the last day by 166 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 2 million shares were bought and sold for approximately $25.76 million.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -14.47% during the next 3 months and, with a 90% probability hold a price between $8.50 and $10.74 at the end of this 3-month period.

Check out how to make money doing surveys! Ad

FOLD Signals & Forecast

There are few to no technical positive signals at the moment. The Amicus Therapeutics stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $10.96 and $11.80. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Thursday, February 15, 2024, and so far it has fallen -24.64%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely.

Support, Risk & Stop-loss for Amicus Therapeutics stock

There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $0.170 between high and low, or 1.62%. For the last week, the stock has had daily average volatility of 2.62%.

Amicus Therapeutics is oversold on RSI14 (22). Some stocks may drop long and hard while being oversold on RSI before turning, which increases the general risk.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (FOLD) For The Upcoming Trading Day Of Thursday 18th

For the upcoming trading day on Thursday, 18th we expect Amicus Therapeutics to open at $10.56, and during the day (based on 14 day Average True Range), to move between $10.16 and $10.94, which gives a possible trading interval of +/-$0.386 (+/-3.66%) up or down from last closing price. If Amicus Therapeutics takes out the full calculated possible swing range there will be an estimated 7.31% move between the lowest and the highest trading price during the day.

With no support below and resistance from accumulated volume @ $11.48, some $0.93 (8.82%) from the current price of $10.55, our system finds the risk reward not very attractive.

Is Amicus Therapeutics stock A Buy?

Amicus Therapeutics holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

Current score: -4.396 Sell Candidate Unchanged

Predicted Opening Price for Amicus Therapeutics of Thursday, April 18, 2024

Fair opening price April 18, 2024 Current price
$10.56 ( 0.126%) $10.55

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for FOLD

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 10.73 1.74 %
R2 10.67 1.12 %
R1 10.63 0.742 %
Current price: 10.55
Support S1 10.50 -0.489 %
S2 10.46 -0.87 %
S3 10.39 -1.48 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 12.95 22.75 %
R2 12.43 17.82 %
R1 11.48 8.82 %
Current price 10.55
Support S1 0 .
S2 0 .
S3 0 .

FAQ

What is the symbol for Amicus Therapeutics Stock and on which exchange is it traded?
The symbol for Amicus Therapeutics is FOLD and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Amicus Therapeutics Stock?
Amicus Therapeutics holds several negative signals and is within a very wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock.

How to buy Amicus Therapeutics Stock?
Amicus Therapeutics Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Amicus Therapeutics Stock.

What's the current price of Amicus Therapeutics Stock?
As of the end of day on the 2024-04-17, the price of an Amicus Therapeutics (FOLD) share was $10.55.

What is the 52-week high and low for Amicus Therapeutics Stock?
The 52-week high for Amicus Therapeutics Stock is $14.57 and the 52-week low is $9.70.

What is the market capitalization of Amicus Therapeutics Stock?
As of the 2024-04-17, the market capitalization of Amicus Therapeutics is 3.116B.

When is the next earnings date for Amicus Therapeutics?
The upcoming earnings date for Amicus Therapeutics is May 08, 2024.
Click to get the best stock tips daily for free!

About Amicus Therapeutics

Amicus Therapeutics Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzym... FOLD Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT